Navigation Links
N30 Pharma Announces Financing, Expansion of Board
Date:10/28/2008

BOULDER, Colo., Oct. 28 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that regulate nitric oxide bioavailability, announced today that it has completed a financing and expanded its Board of Directors.

N30 will use proceeds from this financing to advance its clinical program in Cystic Fibrosis and expand its discovery and preclinical research in the area of small molecule drugs that modulate nitric oxide bioavailability in cardiopulmonary diseases. The financing is the company's second since its formation in 2007. Joining the company's Board of Directors are Arnold Snider and Marc Elia. Mr. Snider will assume the role of Chairman of the Board.

Mr. Snider previously founded and managed Deerfield Management, a New York-based multi-billion dollar hedge fund focused on healthcare and life-sciences companies. Mr. Snider is also on the Board of Directors of the Christopher and Dana Reeve Foundation and is a trustee of Davidson College.

Mr. Elia co-founded N30 while at Tiger Management, a New York hedge fund, and has had previous roles in life sciences corporate strategy at Chiron Corporation and L.E.K. Consulting.

"I am pleased with our investors' ongoing commitment to the major clinical potential of N30 Pharma, particularly in difficult economic times. In addition, I welcome Arnie and Marc to their roles on the Board. Arnie is widely regarded as one of the premier healthcare investors in the world. Marc brings a multitude of talents and intellect to the N30 Board. I look forward to drawing on their expertise and long experience with biopharmaceutical companies as we continue to move N30 forward," commented Charles Scoggin, M.D., President and CEO of N30.

About N30 Pharma

N30 Pharma is a clinical-stage company developing s-nitrosothiol therapies for major unmet needs in cardiopulmonary diseases. S-nitrosothiols are endogenous molecules that store and transduce nitric oxide, and are critical modulators of airway and vascular smooth muscle tone and inflammatory responses. N30 is a privately held company headquartered in Boulder, Colorado.


'/>"/>
SOURCE N30 Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
2. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
3. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
4. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
5. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
6. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
7. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
8. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
9. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
10. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
11. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , December 8, 2016 ... expanded its customisable SureSeq™ NGS panel range with the launch ... fast and cost-effective study of variants in familial hypercholesterolemia (FH). ... variation (CNV) detection on a single small panel and allows ... content. This includes all exons for LDLR , ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... PRINCETON, N.J. , Dec. 8, 2016 /PRNewswire/ ... a late-stage biopharmaceutical company focused on developing and ... is an unmet medical need, announced today the ... trial with SGX942 (dusquetide), a first-in-class Innate Defense ... (OM) in head and neck cancer patients undergoing ...
(Date:12/8/2016)... 8, 2016 Savannah River Remediation LLC ... selected NewTechBio,s NT-MAX Lake & Pond Sludge ... bacteria, in conjunction with Hexa Armor/ Rhombo cover ... National Pollutant Discharge Elimination System requirements. ... steady history of elevated pH levels, above 8.5, ...
Breaking Biology Technology:
(Date:11/28/2016)... Nov. 28, 2016 "The ... of 16.79%" The biometric system market is in ... in the near future. The biometric system market is ... 2022, at a CAGR of 16.79% between 2016 and ... of biometric technology in smartphones, rising use of biometric ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by Authentication ... (Hardware and Software), Function (Contact and Non-contact), Application, and Region - Global ... from USD 10.74 Billion in 2015 to reach USD 32.73 Billion by ... Continue Reading ... ...
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
Breaking Biology News(10 mins):